Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Jan 26

PMID 31979205

Citations 41

Authors

Jan Dorrie

Niels Schaft

Gerold Schuler

Beatrice Schuler-Thurner

Affiliations

Soon will be listed here.

Abstract

Over the last two decades, dendritic cell (DC) vaccination has been studied extensively as active immunotherapy in cancer treatment and has been proven safe in all clinical trials both with respect to short and long-term side effects. For antigen-loading of dendritic cells (DCs) one method is to introduce mRNA coding for the desired antigens. To target the whole antigenic repertoire of a tumor, even the total tumor mRNA of a macrodissected biopsy sample can be used. To date, reports have been published on a total of 781 patients suffering from different tumor entities and HIV-infection, who have been treated with DCs loaded with mRNA. The majority of those were melanoma patients, followed by HIV-infected patients, but leukemias, brain tumors, prostate cancer, renal cell carcinomas, pancreatic cancers and several others have also been treated. Next to antigen-loading, mRNA-electroporation allows a purposeful manipulation of the DCs' phenotype and function to enhance their immunogenicity. In this review, we intend to give a comprehensive summary of what has been published regarding clinical testing of ex vivo generated mRNA-transfected DCs, with respect to safety and risk/benefit evaluations, choice of tumor antigens and RNA-source, and the design of better DCs for vaccination by transfection of mRNA-encoded functional proteins.

Citing Articles

Recent advances and perspectives on the development of circular RNA cancer vaccines.

Gong Z, Hu W, Zhou C, Guo J, Yang L, Wang B NPJ Vaccines. 2025; 10(1):41.

PMID: 40025038 PMC: 11873252. DOI: 10.1038/s41541-025-01097-x.

Revolutionizing Dentistry: Preclinical Insights and Future Applications of mRNA Vaccines in Dentistry-A Narrative Review.

Koren L, Koren A, Likic R, Katanec T Dent J (Basel). 2025; 13(2).

PMID: 39996953 PMC: 11854559. DOI: 10.3390/dj13020079.

Cytokine-overexpressing dendritic cells for cancer immunotherapy.

Han J, Wang H Exp Mol Med. 2024; 56(12):2559-2568.

PMID: 39617785 PMC: 11671598. DOI: 10.1038/s12276-024-01353-5.

Immunotherapy Vaccines for Prostate Cancer Treatment.

He J, Wu J, Li Z, Zhao Z, Qiu L, Zhu X Cancer Med. 2024; 13(20):e70294.

PMID: 39463159 PMC: 11513549. DOI: 10.1002/cam4.70294.

The Role of the Large T Antigen in the Molecular Pathogenesis of Merkel Cell Carcinoma.

Myrda J, Bremm F, Schaft N, Dorrie J Genes (Basel). 2024; 15(9).

PMID: 39336718 PMC: 11431464. DOI: 10.3390/genes15091127.

References

Amin A, Dudek A, Logan T, Lance R, Holzbeierlein J, Knox J . Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015; 3:14. PMC: 4404644. DOI: 10.1186/s40425-015-0055-3. View

Bol K, Aarntzen E, Pots J, Olde Nordkamp M, van de Rakt M, Scharenborg N . Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother. 2016; 65(3):327-39. PMC: 4779136. DOI: 10.1007/s00262-016-1796-7. View

Maccalli C, Giannarelli D, Capocefalo F, Pilla L, Fonsatti E, Di Giacomo A . Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Oncoimmunology. 2016; 5(2):e1071007. PMC: 4801454. DOI: 10.1080/2162402X.2015.1071007. View

Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G . Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12):1325-33. PMC: 4397277. DOI: 10.1200/JCO.2014.57.4244. View

Kyte J, Kvalheim G, Lislerud K, Straten P, Dueland S, Aamdal S . T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2006; 56(5):659-75. PMC: 11030282. DOI: 10.1007/s00262-006-0222-y. View

Boczkowski D, Nair S, Snyder D, Gilboa E . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996; 184(2):465-72. PMC: 2192710. DOI: 10.1084/jem.184.2.465. View

Antonia S, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N . Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006; 12(3 Pt 1):878-87. DOI: 10.1158/1078-0432.CCR-05-2013. View

Aarntzen E, Figdor C, Adema G, Punt C, de Vries I . Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother. 2008; 57(10):1559-68. PMC: 2491428. DOI: 10.1007/s00262-008-0553-y. View

Galsky M, Wang H, Hahn N, Twardowski P, Pal S, Albany C . Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2017; 73(5):751-759. DOI: 10.1016/j.eururo.2017.12.001. View

10.

Zitvogel L, Mayordomo J, Tjandrawan T, DeLeo A, Clarke M, Lotze M . Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996; 183(1):87-97. PMC: 2192415. DOI: 10.1084/jem.183.1.87. View

11.

Nair S, Morse M, Boczkowski D, Cumming R, Vasovic L, Gilboa E . Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 2002; 235(4):540-9. PMC: 1422470. DOI: 10.1097/00000658-200204000-00013. View

12.

Bassani-Sternberg M, Digklia A, Huber F, Wagner D, Sempoux C, Stevenson B . A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three.... Front Immunol. 2019; 10:1832. PMC: 6694698. DOI: 10.3389/fimmu.2019.01832. View

13.

Burnet F . The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13:1-27. DOI: 10.1159/000386035. View

14.

ORourke M, Johnson M, Lanagan C, See J, OConnor L, Slater G . Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res. 2007; 17(5):316-22. DOI: 10.1097/CMR.0b013e3282c3a73b. View

15.

Reap E, Suryadevara C, Batich K, Sanchez-Perez L, Archer G, Schmittling R . Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Res. 2017; 78(1):256-264. PMC: 5754236. DOI: 10.1158/0008-5472.CAN-17-0469. View

16.

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

17.

Timmerman J, Czerwinski D, Davis T, Hsu F, Benike C, Hao Z . Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002; 99(5):1517-26. DOI: 10.1182/blood.v99.5.1517. View

18.

Engell-Noerregaard L, Hansen T, Andersen M, Straten P, Marie Svane I . Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2008; 58(1):1-14. PMC: 11030652. DOI: 10.1007/s00262-008-0568-4. View

19.

Sprooten J, Ceusters J, Coosemans A, Agostinis P, de Vleeschouwer S, Zitvogel L . Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology. 2019; 8(11):e1638212. PMC: 6791419. DOI: 10.1080/2162402X.2019.1638212. View

20.

Hellmann M, Snyder A . Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. Immunity. 2017; 47(2):221-223. DOI: 10.1016/j.immuni.2017.08.001. View